A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

about

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

P2860

Q26738509-65EED990-F354-42B3-BFBA-3902D90E8CC5 Q36007020-2A1E338D-A788-4A90-A7FF-E9F154EF9E81 Q52638911-064761D2-D191-4C1B-AD83-4F3B0E92C68B

P2860

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

Item

http://www.wikidata.org/entity/Q36452230

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@ast

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@en

type

Item

label

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@ast

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@en

prefLabel

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@ast

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@en

P1476

A Phase III Study of Balugrast ...... With Doxorubicin and Docetaxel

@en

P2093

Liat Adar

http://www.w3.org/2001/XMLSchema#string

Noa Avisar

http://www.w3.org/2001/XMLSchema#string

Oleg Gladkov

http://www.w3.org/2001/XMLSchema#string

Steve Barash

http://www.w3.org/2001/XMLSchema#string

Yaroslav Shparyk

http://www.w3.org/2001/XMLSchema#string

P2860

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.

Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Pharmacokinetics and pharmacodynamics of pegfilgrastim.

P304

7-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2015-0152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Igor N. Bondarenko

Vladimir Moiseyenko

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26668251

http://www.w3.org/2001/XMLSchema#string

P932

4709202

http://www.w3.org/2001/XMLSchema#string

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

about

P2860

P2860

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932